Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...

Related Keywords

United Kingdom ,Houston ,Texas ,United States ,Poland ,British ,Polish ,Jenene Thomas ,Walter Klemp ,John Paul Waymack Moleculin ,Liposomal Annamycin ,Priebe Moleculin ,Wolfram Dempke Moleculin ,Exchange Commission ,Drug Administration ,Securities Exchange ,Linkedin ,British Journal Of Cancer Research ,Facebook ,Moleculin Biotech Inc ,Nasdaq ,Twitter ,British Journal ,Moleculin Biotech ,After Induction Therapy ,Wolfram Dempke ,European Chief Medical Officer ,John Paul Waymack ,Senior Chief Medical Officer ,Waldemar Priebe ,Advisory Board ,Partial Response ,Fast Track Status ,Orphan Drug Designation ,Transcription Modulator ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Nc ,Biotechnology ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,